Advertisement

Indian Journal of Microbiology

, Volume 59, Issue 4, pp 514–524 | Cite as

Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis

  • Wenli FengEmail author
  • Jing YangEmail author
  • Zhiqin Xi
  • Ying Ji
  • Xin Zhu
  • Lu Yang
  • Yan Ma
Original research article
  • 47 Downloads

Abstract

Vulvovaginal candidiasis (VVC), caused by Candida albicans, affects women’s health and life. We aimed to explore the correlation between ERG3 as well as Efg1 mutation/overexpression and azoles-resistance, and the correlation between ERG3 and Efg1 mRNA expression in C. albicans. First, C. albicans was isolated from clinical VVC patients. ERG3 and Efg1 mutations were detected by polymerase chain reaction (PCR) and sequencing, and the expression levels of these two genes were also identified by qRT-PCR. Correlations between mutation/overexpression of ERG3/Efg1 and azoles-resistance as well as ERG3 and Efg1 mRNA expression were analyzed. Based on the ERG3 sequencing, the results showed that there were 2 missense mutation sites, 1 nonsense mutation site, and 4 silent mutation sites, while 1 missense mutation sites, 1 nonsense mutation site, and 12 silent mutation sites were found in Efg1. Furthermore, the mRNA levels of ERG3 gene in the strains sensitive to FCA, ITR or VRC were higher than those in the strains resistant to FCA, ITR, VRC (P < 0.05). While for the mRNA levels of Efg1, susceptible strains were lower than resistant strains. Besides, there was a significant linear negative correlation between ERG3 and Efg1 mRNA expression (r = − 0.614, P < 0.001).

Keywords

Candida albicans Azoles Drug resistance ERG3 Efg1 

Notes

Acknowledgements

This work was supported by Basic Research Project supported by Shanxi Province, China (Program No. 201701D121171), Research and Development Key Projects of Shanxi Province (Program No. 201603D321063), Research Project Supported by Health and Family Planning Commission of Shanxi Province, China (Program No. 201601050). Meanwhile, the project was supported by the Science & Technology Innovation Foundation for Univerisities in Shanxi Province, China (Program No. 20161118).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Elfeky DS, Gohar NM, El-Seidi EA, Ezzat MM, Aboelew SH (2016) Species identification and antifungal susceptibility pattern of Candida isolates in cases of vulvovaginal candidiasis. Alex J Med 52:269–277.  https://doi.org/10.1016/j.ajme.2015 CrossRefGoogle Scholar
  2. 2.
    Gharaei A, Erahimzadeh A, Khorashad ARS, Jorjani O, Jamshidi A et al (2015) Determination of prevalancy and species of vulvovaginal candidiasis and clinical findings correlation. J Gorgan Univ Med Sci 17:109–113Google Scholar
  3. 3.
    Matheson A, Mazza D (2017) Recurrent vulvovaginal candidiasis: a review of guideline recommendations. Aust N Z J Obstet Gynaecol.  https://doi.org/10.1111/ajo.12592 CrossRefPubMedGoogle Scholar
  4. 4.
    Fan SR, Bai FY, Liao QP, Liu ZH, Li J et al (2008) Genotype distribution of Candida albicans strains associated with different conditions of vulvovaginal candidiasis, as revealed by microsatellite typing. Sex Transm Infect 84:103–106.  https://doi.org/10.1136/sti.2007.025700 CrossRefPubMedGoogle Scholar
  5. 5.
    Cowen LE, Steinbach WJ (2008) Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7:747.  https://doi.org/10.1128/EC.00041-08 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Maurizio S, Brunella P, Cornelia LFR (2015) Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses 58:2–13.  https://doi.org/10.1111/myc.12330 CrossRefGoogle Scholar
  7. 7.
    Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS et al (2016) Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol.  https://doi.org/10.3389/fmicb.2016.02173 CrossRefPubMedGoogle Scholar
  8. 8.
    Sanglard D, Ischer F, Bille L (1998) Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42:241–253.  https://doi.org/10.1097/00001813-199802000-00010 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    White TC, Holleman S, Dy F, Mirels LF, Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46:1704–1713.  https://doi.org/10.1128/AAC.46.6.1704-1713.2002 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Perea S, López-Ribot JL, Kirkpatrick WR, Mcatee RK, Santillán RA et al (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676–2684CrossRefGoogle Scholar
  11. 11.
    Strzelczyk JK, Slemp-Migiel A, Rother M, Gołąbek K, Wiczkowski A (2013) Nucleotide substitutions in the Candida albicans ERG11 gene of azole-susceptible and azole-resistant clinical isolates. Acta Biochim Polon 60:547.  https://doi.org/10.1016/B978-0-12-420067-8.00023-4 CrossRefPubMedGoogle Scholar
  12. 12.
    Feng W, Yang J, Xi Z, Qiao Z, Lv Y et al (2017) Mutations and/or over expressions of ERG4 and ERG11 genes in clinical azoles-resistant isolates of Candida albicans. Microbial Drug Resist (Larchmont, NY) 23:563–570.  https://doi.org/10.1089/mdr.2016.0095 CrossRefGoogle Scholar
  13. 13.
    Feng W, Yang J, Wang Y, Chen J, Xi Z et al (2016) ERG11 mutations and upregulation in clinical itraconazole-resistant isolates of Candida krusei. Can J Microbiol 62:938.  https://doi.org/10.1139/cjm-2016-0055 CrossRefPubMedGoogle Scholar
  14. 14.
    Yang J, Feng W, Wang Y, Chen J, Xi Z et al (2016) Mutation and elevated expression of ERG5 gene in anti-fungal drugs of Candida albicans. China J Health Insp 4:542–545Google Scholar
  15. 15.
    Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL et al (2015) Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis. Antimicrobial Agents Chemother 59:5942.  https://doi.org/10.1128/AAC.01358-15 CrossRefGoogle Scholar
  16. 16.
    Vale-Silva LA, Coste AT, Ischer F, Parker JE, Kelly SL et al (2012) Azole resistance by loss of function of the sterol Δ5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob Agents Chemother 56:1960–1968.  https://doi.org/10.1128/AAC.05720-11 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lotfali E, Ghajari A, Kordbacheh P, Zaini F, Mirhendi H et al (2017) Regulation of ERG3, ERG6, and ERG11 Genes in antifungal-resistant isolates of Candida parapsilosis. Iran Biomed J 21:275–281.  https://doi.org/10.18869/acadpub.ibj.21.4.275 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Akins RA (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43:285–318.  https://doi.org/10.1080/13693780500138971 CrossRefPubMedGoogle Scholar
  19. 19.
    Lo HJ, Wang JS, Lin CY, Chen CG, Hsiao TY, Hsu CT, Su CL, Fann MJ, Ching YT, Yang YL (2005) Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans. Antimicrob Agents Chemother 49:1213–1215.  https://doi.org/10.1128/AAC.49.3.1213-1215.2005 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Saputo S, Kumar A, Krysan DJ (2014) Efg1 directly regulates ACE2 expression to mediate cross talk between the cAMP/PKA and RAM pathways during Candida albicans morphogenesis. Eukaryot Cell 13:1169.  https://doi.org/10.1128/EC.00148-14 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Su H-c, Cheng B, Shi X-m (2010) The difference of EFG1 and HGC1 expression between the myceial and yeast from of Candida albicans. Chin J Dermatol Vener Dis 24:304–306Google Scholar
  22. 22.
    Feng W, Yang J, Yang L, Li Q, Zhu X et al (2018) Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications. Experimental and Therapeutic Medicine 15:1217–1224.  https://doi.org/10.3892/etm.2017.5518 CrossRefPubMedGoogle Scholar
  23. 23.
    Casalinuovo IA, Di FP, Garaci E (2004) Fluconazole resistance in Candida albicans: a review of mechanisms. Eur Rev Med Pharmacol Sci 8:69PubMedGoogle Scholar
  24. 24.
    Florent M, Fabrice P, Claire L, Michel M, Patrice LP (2012) Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J Antimicrob Chemother 67:2131–2138.  https://doi.org/10.1093/jac/dks186 CrossRefGoogle Scholar
  25. 25.
    Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J (2003) Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 47:2404–2412.  https://doi.org/10.1128/aac.47.8.2404-2412.2003 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Prasad T, Hameed S, Manoharlal R, Biswas S, Mukhopadhyay CK et al (2010) Morphogenic regulator EFG1 affects the drug susceptibilities of pathogenic Candida albicans. FEMS Yeast Res 10:587–596.  https://doi.org/10.1111/j.1567-1364.20 CrossRefPubMedGoogle Scholar

Copyright information

© Association of Microbiologists of India 2019

Authors and Affiliations

  1. 1.The Department of DermatovenereologyThe Second Hospital of Shanxi Medical UniversityTaiyuanChina

Personalised recommendations